Questcor Pharmaceuticals (Nasdaq: QCOR) reported earnings on Feb. 26. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended Dec. 31 (Q4), Questcor Pharmaceuticals beat expectations on revenues and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue increased significantly. GAAP earnings per share expanded significantly.

Gross margins dropped, operating margins grew, net margins dropped.

Revenue details
 Questcor Pharmaceuticals logged revenue of $160.5 million. The eight analysts polled by S&P Capital IQ expected revenue of $143.0 million on the same basis. GAAP reported sales were much higher than the prior-year quarter's $75.5 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at $1.03. The six earnings estimates compiled by S&P Capital IQ anticipated $0.90 per share. GAAP EPS of $1.03 for Q4 were 115% higher than the prior-year quarter's $0.48 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 94.3%, 40 basis points worse than the prior-year quarter. Operating margin was 59.0%, 240 basis points better than the prior-year quarter. Net margin was 38.6%, 330 basis points worse than the prior-year quarter.

Looking ahead
 Next quarter's average estimate for revenue is $147.6 million. On the bottom line, the average EPS estimate is $0.84.

Next year's average estimate for revenue is $621.7 million. The average EPS estimate is $3.68.

Investor sentiment
 The stock has a two-star rating (out of five) at Motley Fool CAPS, with 467 members out of 530 rating the stock outperform, and 63 members rating it underperform. Among 134 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 105 give Questcor Pharmaceuticals a green thumbs-up, and 29 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Questcor Pharmaceuticals is outperform, with an average price target of $41.86.

Can your portfolio provide you with enough income to last through retirement? You'll need more than Questcor Pharmaceuticals. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.